An affordable antidepressant has been found in a clinical trial to reduce the risk of hospitalization in high-risk adults with recently diagnosed COVID-19, according to a study published in The Lancet Global Health.
The drug, known as fluvoxamine, is a selective serotonin reuptake inhibitor (SSRI) commonly used in the treatment of depression, anxiety, obsessive-compulsive disorder and other mood disorders. Its low price makes it a desirable treatment option for less wealthy nations, the researchers wrote.
Researchers began looking into the drug during the height of the pandemic because of the antidepressant’s ability to reduce inflammation, according to The New York Times. The researchers thus hypothesized that the drug may allow the body to quell an overwhelming response to a COVID-19 infection.
Other studies have come out in the past months on fluvoxamine that also showed promising results; however, no study has been as large as the one published Wednesday, according to the Times.